Canada markets open in 39 minutes

Instil Bio, Inc. (TIL)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
10.75+0.04 (+0.37%)
At close: 04:00PM EDT
10.50 -0.25 (-2.33%)
After hours: 04:07PM EDT

Instil Bio, Inc.

3963 Maple Avenue
Suite 350
Dallas, TX 75219
United States
972 499 3350
https://instilbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 49

Key Executives

NameTitlePayExercisedYear Born
Mr. Bronson CrouchChairman & CEO672.37kN/A1973
Dr. Sandeep Laumas M.D.CFO & Chief Business Officer489.14kN/A1969
Dr. Mark E. Dudley Ph.D.Chief Scientific OfficerN/AN/AN/A
Dr. Robert Hawkins MBBS, Ph.D.Head of Research & Development218.72kN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Corporate Governance

Instil Bio, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.